Cure SMA Unveils Initiatives to Improve Clinical Trial Accessibility

News
Article

Cure SMA introduces tools aiding in SMA clinical trial navigation and participation empowerment.

Cure SMA is pleased to announce the release of new resources to support our community’s ability to navigate the evolving landscape of SMA clinical trials. These resources are intended to build knowledge in clinical trial procedures and preparation, to enhance awareness regarding actively recruiting clinical trials and sites, and to empower our community in their decision-making. 

  • SMA Registry and Clinical Trial Finder: Explore SMA clinical trials with our easy-to-use search widget. Filter by SMA type, location, trial phase, treatment status, and more to find trials that fit individual needs and preferences.
  • Screening Visit Checklist: Prepare for the screening visit with a thorough checklist that organizes medical history and suggests questions to ask the research team.
  • Decoding Informed Consent: Understanding informed consent is crucial! Our handout will guide adults living with SMA and caregivers through the key sections of the informed consent form, ensuring they’re confident in their decision to participate in a clinical trial.
  • Travel Planners (Air and Ground): Manage travel details with ease! Our itineraries will help travel planning and are tailored to the unique needs of the SMA community.

About the Cure SMA Industry Collaboration 

The Cure SMA Industry Collaboration (SMA-IC) was established in 2016 to leverage the experience, expertise, and resources of pharmaceutical and biotechnology companies, as well as other nonprofit organizations involved in the development of spinal muscular atrophy (SMA) therapeutics to more effectively address a range of scientific, clinical, and regulatory challenges. Current members include Cure SMA, Scholar Rock, Biogen, Biohaven Pharmaceuticals, Genentech/Roche, Novartis, Alcyone Therapeutics, NMD Pharma, and SMA Europe.

Related Videos
Michael Levy, MD, PhD
Michael Kaplitt, MD, PhD
Michael Kaplitt, MD, PhD
video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"
Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"
Svetlana Blitshteyn, MD, FAAN, director and founder of Dysautonomia Clinic
© 2024 MJH Life Sciences

All rights reserved.